Bioarctic Neuroscience has announced that the first patients in Sweden have been treated with BAN2401 in a clinical study for patients with an early type of Alzheimer’s disease.
BAN2401 is a monoclonal antibody that has been developed in the laboratory of Professor Lars Lannfeldt at Uppsala University. The study is carried out by the Japanese pharmaceutical company Eisai which is a collaboration partner in the development of the drug candidate.
Three university hospitals in Sweden will participate in the global phase II study which has already been initiated in the United States and in Canada. Further study centers in Europe will also participate. Up to 800 patients with Alzheimer’s disease at an early stage will be recruited and will get five different ways of dosing BAN2401 or placebo.
